Viatris Inc.
HealthcareNASDAQ:VTRS · NASDAQ Global Select
+$0.17 today
Vol 6.16M · Avg 10.75M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-23.9%
avg -0.5%
ROIC
-7.9%
avg 1.0%
ROA
-9.5%
avg -0.2%
Analysis
ROIC is currently the strongest return metric at -7.9% versus its period average of 1.0%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Scott Andrew Smith | Chief Executive Officer & Director | $5.12M | — | 64 | $60,435.00 | <0.01% |
Paul Campbell | Interim CFO, Chief Accounting Officer & Corporate Controller | $3.70M | — | 59 | $366,288.00 | 0.03% |
Corinne Le Goff | Chief Commercial Officer | $2.33M | — | 61 | $0.00 | <0.01% |
Matthew Joseph Maletta | Chief Legal Officer | $2.21M | — | 54 | $59,323.00 | <0.01% |
Theodora Mistras | Executive Officer | $2.19M | — | 44 | $4,141.00 | <0.01% |
Andrew Enrietti | Chief Administrative & Transformation Officer | $1.94M | — | 41 | $60,435.00 | <0.01% |
Hemanth Jacob Varghese | Chief Strategy Officer | — | — | 50 | — | — |
Peter McCormick | Chief Supply Officer | — | — | — | — | — |
Philippe Martin | Chief R&D Officer | — | — | 50 | — | — |
Ramkumar V. Rayapureddy | Chief Information Officer | — | — | — | — | — |
William Szablewski | Head of Investor Relations & Capital Markets | — | — | — | — | — |
Lara Ramsburg | Chief People & Corporate Affairs Officer | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
3
$224,942.01
Sells
2
$355,583.62
Net Sentiment
$130,641.62
Net selling
Most Active
SIMMONS DAVID S
2 transactions
Analysis
Insiders reported 3 buys worth $224,942.01 and 2 sells worth $355,583.62 over the last 12 months. That adds up to net selling of $130,641.62. SIMMONS DAVID S was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | +3.8% | N/A0 analysts |
| Revenue | N/A | N/A | +11.5% | +3.4% (14yr)2 analysts |
| Net Income | N/A | N/A | +9.8% | N/A2 analysts |
| EBIT | N/A | N/A | +9.6% | -18.1% (14yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +11.5% over three years. Forward estimates point to Revenue at +3.4% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Roivant Sciences Ltd.
NASDAQ:ROIV
$21.61B
Exact Sciences Corporation
EXAS
$20.03B
Moderna, Inc.
NASDAQ:MRNA
$19.80B
Neurocrine Biosciences, Inc.
NASDAQ:NBIX
$16.06B
BridgeBio Pharma, Inc.
NASDAQ:BBIO
$13.08B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.11B
Elanco Animal Health Incorporated
NYSE:ELAN
$12.07B
Dr. Reddy's Laboratories Limited
NYSE:RDY
$11.07B
Baxter International Inc.
NYSE:BAX
$10.77B
Regencell Bioscience Holdings Limited
NASDAQ:RGC
$9.31B
Who manages VTRS?
Viatris Inc. (VTRS) lists 12 active executives. The top listed executive is Hemanth Jacob Varghese, Chief Strategy Officer.
Are VTRS insiders buying or selling?
Recent insider activity shows net selling of $13.70M.
Explore More
Continue the stock analysis
Jump to another research area for this company.